LEGN

Business Context and Reporting Period

Company: Legend Biotech Corporation
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Nine months ended September 30, 2024
Business Overview: Legend Biotech is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology. Its lead product, CARVYKTI (cilta-cel), is a CAR-T cell therapy for multiple myeloma, developed in collaboration with Janssen Biotech, Inc. The company also holds a global license agreement with Novartis for DLL3-targeting therapies.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 114% to $440.7 million, driven by a 114% increase in collaboration revenue ($314.6 million) due to higher CARVYKTI sales and a 244% increase in license revenue ($120.1 million) from milestones under the Janssen Agreement and the Novartis License Agreement.
• Improved Net Loss: Net loss narrowed by 46% to $203.3 million, primarily due to significant revenue growth and the absence of an $85.8 million fair value loss on warrant liability recorded in the prior year.
• Expense Increases: Operating expenses rose significantly. Research and Development (R&D) increased by 12% to $309.1 million, and Selling and Distribution expenses increased by 63% to $98.6 million, reflecting commercial expansion and manufacturing ramp-up.
• Liquidity Shift: While total liquidity remained robust at approximately $1.2 billion, the composition shifted. Cash and cash equivalents decreased by $818.6 million, largely offset by a massive increase in time deposits (from $30.3 million to $753.1 million) as the company deployed excess cash into short-term investments.

Guidance, Outlook, and Risks

• Outlook: Management expects to achieve operating profit in 2026. The company believes its current liquidity of $1.2 billion provides a financial runway into 2026.
• Commercial Highlights: CARVYKTI net trade sales reached approximately $286 million for the period, representing 87.6% year-over-year growth. The product received FDA label expansion for second-line treatment and NMPA approval in China for fourth-line treatment.
• Strategic Investments: The company announced plans for a new R&D facility in Philadelphia and initiated commercial production at its Obelisc facility in Ghent, Belgium.
• Risks and Contingencies:
  • Capital Requirements: The company expects to continue incurring operating losses and significant capital expenditures for manufacturing and R&D. Additional financing may be required if revenue growth does not meet expectations.
  • Macroeconomic Factors: Inflation, supply chain constraints, and geopolitical conflicts could increase costs or disrupt operations, though no material impact has been observed to date.
  • Regulatory and Clinical Risks: Future success depends on regulatory approvals, clinical trial results, and the ability to maintain patent protection.

Key Facts for Investor Verification

• Revenue Composition: Verify the sustainability of the $120.1 million in license revenue, which includes $75.1 million from Janssen milestones and $45.0 million from the Novartis agreement, as these are non-recurring or milestone-driven.
• Liquidity Quality: Confirm the accessibility of the $753.1 million in time deposits and the terms of withdrawal, as this represents the majority of the company's liquid assets.
• Debt Obligations: Review the terms of the $296.6 million "Collaboration Interest-Bearing Advanced Funding" from Janssen, noting it is repayable from future collaboration profits or milestones rather than cash flow.
• Profitability Timeline: Assess the feasibility of the 2026 operating profit target given the current trajectory of increasing R&D and commercialization expenses.
• Novartis Deal Execution: Monitor the progress of the Novartis collaboration (LB2102) and the recognition of future milestone payments or royalties.